Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate
Xiaochun Zhu(Amgen (United States)), Raju Subramanian(Gilead Sciences (United States)), Xiping Zhang(Amgen (United States)), J. Greg Slatter(Amgen (United States)), Molly R. Deane(Amgen (United States)), Maurice G. Emery(Amgen (United States)), Gary L. Skiles, Dean Hickman, Anna Akrami(Amgen (United States))
Cited by 5
Related Papers
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325
Comparison of Information-Dependent Acquisition, SWATH, and MS<sup>All</sup> Techniques in Metabolite Identification Study Employing Ultrahigh-Performance Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry
|Analytical Chemistry|2013|211
Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry
|Journal of Mass Spectrometry|2006|153
Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors
|Journal of Medicinal Chemistry|2011|120